It is well known that the progression of heart failure is closely linked to the renin-angiotensin-aldosterone system and that the pharmacological modulation of RAAS by ACE inhibitors, aldosterone and angiotensin II (Ang II) type 1 receptor antagonists, or direct renin inhibitors can be beneficial for managing patients with hypertension and heart failure (McMurray et al., 2014; Solomon et al., 2017; Cosentino et al., 2019). The gene discussed is ACE; the disease is hypertensive disorder.